The BIT drug trial mentions no effect on CD4+ T cells which are the main barrier to a cure.
https://www.genengnews.com/topics/g...tent-hiv-1-offering-hope-of-functional-cures/
CD4+ T cells have been the most studied of the cellular reservoirs in which HIV-1 can persist. A small fraction of resting CD4+ T cells will harbor HIV-1, even during ART, and are considered to be “the major obstacle to HIV-1 eradication,” the authors point out. “Latent HIV-1 infection in resting CD4+ T cells is the primary cause of the barrier to a functional cure.”
- Forums
- ASX - By Stock
- BIT
- $10 Billion Deal
$10 Billion Deal, page-130
-
- There are more pages in this discussion • 13,138 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIT (ASX) to my watchlist
|
|||||
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $28.87M |
Open | High | Low | Value | Volume |
3.3¢ | 3.3¢ | 3.2¢ | $17.40K | 542.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 17000 | 3.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.3¢ | 120000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 17000 | 0.031 |
8 | 342305 | 0.030 |
5 | 1208888 | 0.029 |
4 | 468000 | 0.028 |
2 | 537000 | 0.027 |
Price($) | Vol. | No. |
---|---|---|
0.033 | 120000 | 2 |
0.034 | 100000 | 1 |
0.035 | 317251 | 4 |
0.036 | 460000 | 2 |
0.037 | 537816 | 2 |
Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |